MAOA and early-onset autosomal dominant Alzheimer disease: This profile is pharmacologically relevant, as selective MAO-B inhibitors are prioritized in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, due to their lower risk of side effects associated with MAO-A inhibition (e.g., serotonin syndrome).